Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.
Tirzepatide is a first-in-class, once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Given the tight link between hyperglycemia, adiposity, and cardiovascular disease, tirzepatide has rapidly gained interest as a broader cardiometabolic intervention. This narrat...
| Publicado en: | Clinical Medicine Insights: Cardiology Vol. 20; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
6/16/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |